Skip Nav Destination
Issues
1 November 2008
-
Cover Image
Cover Image
MMP-2 expression in tumor-associated macrophages. Shown here is immunofluorescence co-localization (yellow) of macrophages (red) and MMP-2 (green) in a high-grade invasive epithelial ovarian carcinoma (nuclei are stained with Hoechst [blue]). Negative biobehavioral factors such as depressive symptoms and life stress were associated with significantly higher MMP-9 levels in tumor-associated macrophages. For further details, please see the report by Lutgendorf and colleagues on page 6839 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
CCR Drug Updates
Molecular Pathways
Perspective
Review
Human Cancer Biology
Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage
Kenichi Koyama; Hiroshi Kagamu; Satoru Miura; Toru Hiura; Takahiro Miyabayashi; Ryo Itoh; Hideyuki Kuriyama; Hiroshi Tanaka; Junta Tanaka; Hirohisa Yoshizawa; Koh Nakata; Fumitake Gejyo
BRCA1 5083del19 Mutant Allele Selectively Up-Regulates Periostin Expression In vitro and In vivo
Barbara Quaresima; Francesco Romeo; Maria C. Faniello; Maddalena Di Sanzo; Chang-Gong Liu; Annamaria Lavecchia; Cristian Taccioli; Eugenio Gaudio; Francesco Baudi; Francesco Trapasso; Carlo M. Croce; Giovanni Cuda; Francesco Costanzo
Recurrence of Urothelial Carcinoma of the Bladder: A Role for Insulin-Like Growth Factor-II Loss of Imprinting and Cytoplasmic E-Cadherin Immunolocalization
Emma M. Gallagher; Deirdre M. O'Shea; Patricia Fitzpatrick; Michèle Harrison; Breege Gilmartin; Jenny A. Watson; Trevor Clarke; Martin O. Leonard; Aloysius McGoldrick; Maria Meehan; Chanel Watson; Fiona Furlong; Patrick O'Kelly; John M. Fitzpatrick; Peter A. Dervan; Anthony O'Grady; Elaine W. Kay; Amanda McCann
Cancer Therapy: Preclinical
Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
Tan Min Chin; Margaret P. Quinlan; Anurag Singh; Lecia V. Sequist; Thomas J. Lynch; Daniel A. Haber; Sreenath V. Sharma; Jeffrey Settleman
Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
Robert J. Kinders; Melinda Hollingshead; Sonny Khin; Larry Rubinstein; Joseph E. Tomaszewski; James H. Doroshow; Ralph E. Parchment; the National Cancer Institute Phase 0 Clinical Trials Team
A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors
Madeleine S.Q. Kortenhorst; Marianna Zahurak; Shabana Shabbeer; Sushant Kachhap; Nathan Galloway; Giovanni Parmigiani; Henk M.W. Verheul; Michael A. Carducci
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Oihana Murillo; Ainhoa Arina; Sandra Hervas-Stubbs; Anjana Gupta; Brandon McCluskey; Juan Dubrot; Asís Palazón; Arantza Azpilikueta; Maria C. Ochoa; Carlos Alfaro; Sarai Solano; José L. Pérez-Gracia; Babatunde O. Oyajobi; Ignacio Melero
Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma
Eiji Sato; Toshihiko Torigoe; Yoshihiko Hirohashi; Hiroshi Kitamura; Toshiaki Tanaka; Ichiya Honma; Hiroko Asanuma; Kenji Harada; Hideo Takasu; Naoya Masumori; Naoki Ito; Tadashi Hasegawa; Taiji Tsukamoto; Noriyuki Sato
Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer
Lyndee L. Scurr; Alexander D. Guminski; Yoke-Eng Chiew; Rosemary L. Balleine; Raghwa Sharma; Ying Lei; Kylie Pryor; Gerard V. Wain; Alison Brand; Karen Byth; Catherine Kennedy; Helen Rizos; Paul R. Harnett; Anna deFazio
DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma
Arjen Sloots; Cristina Mastini; Florian Rohrbach; Robert Weth; Claudia Curcio; Ute Burkhardt; Elke Jäger; Guido Forni; Federica Cavallo; Winfried S. Wels
Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy
Weihua Song; Hans J.J. van der Vliet; Yu-Tzu Tai; Rao Prabhala; Ruojie Wang; Klaus Podar; Laurence Catley; Masood A. Shammas; Kenneth C. Anderson; Steven P. Balk; Mark A. Exley; Nikhil C. Munshi
Imaging, Diagnosis, Prognosis
Macrophage Inflammatory Protein-3α Is a Novel Serum Marker for Nasopharyngeal Carcinoma Detection and Prediction of Treatment Outcomes
Kai-Ping Chang; Sheng-Po Hao; Jui-Hung Chang; Chih-Ching Wu; Ngan-Ming Tsang; Yun-Shien Lee; Chen-Lung Hsu; Shir-Hwa Ueng; Shiau-Chin Liu; Yu-Lun Liu; Pei-Cih Wei; Yin Liang; Yu-Sun Chang; Jau-Song Yu
Cell Proliferation, Cell Cycle Abnormalities, and Cancer Outcome in Patients with Barrett's Esophagus: A Long-term Prospective Study
Dennis L. Chao; Carissa A. Sanchez; Patricia C. Galipeau; Patricia L. Blount; Thomas G. Paulson; David S. Cowan; Kamran Ayub; Robert D. Odze; Peter S. Rabinovitch; Brian J. Reid
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Jean-Yves Pierga; François-Clément Bidard; Claire Mathiot; Etienne Brain; Suzette Delaloge; Sylvie Giachetti; Patricia de Cremoux; Rémy Salmon; Anne Vincent-Salomon; Michel Marty
Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma
Shigeki Yagyu; Takahiro Gotoh; Tomoko Iehara; Mitsuru Miyachi; Yoshiki Katsumi; Satoko Tsubai-Shimizu; Ken Kikuchi; Shinichi Tamura; Kunihiko Tsuchiya; Toshihiko Imamura; Akiko Misawa-Furihata; Tohru Sugimoto; Tadashi Sawada; Hajime Hosoi
Cancer Therapy: Clinical
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa; Kim-Son H. Nguyen; Byoung C. Cho; Lecia V. Sequist; David M. Jackman; Gregory J. Riely; Beow Y. Yeap; Balázs Halmos; Joo H. Kim; Pasi A. Jänne; Mark S. Huberman; William Pao; Daniel G. Tenen; Susumu Kobayashi
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Annick Desjardins; David A. Reardon; James E. Herndon, II; Jennifer Marcello; Jennifer A. Quinn; Jeremy N. Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D. Bigner; Allan H. Friedman; Henry S. Friedman; James J. Vredenburgh
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Samuel A. Jacobs; Steven H. Swerdlow; Jeffrey Kant; Kenneth A. Foon; Rachel Jankowitz; Stephanie R. Land; Nicholas DeMonaco; Judith Joyce; Jennifer L. Osborn; Terry L. Evans; Patricia M. Schaefer; The Minh Luong
Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
Olatoyosi M. Odenike; Serhan Alkan; Dorie Sher; John E. Godwin; Dezheng Huo; Stephen J. Brandt; Margaret Green; Jingping Xie; Yanming Zhang; David H. Vesole; Patrick Stiff; John Wright; Richard A. Larson; Wendy Stock
Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
Aurélie Petain; Darouna Kattygnarath; Julie Azard; Etienne Chatelut; Catherine Delbaldo; Birgit Geoerger; Michel Barrois; Sophie Séronie-Vivien; Axel LeCesne; Gilles Vassal; On behalf of the Innovative Therapies with Children with Cancer European consortium
A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Kyriakos P. Papadopoulos; Sanjay Goel; Murali Beeram; Alvin Wong; Kavita Desai; Missak Haigentz; María L. Milián; Sridhar Mani; Anthony Tolcher; Alshad S. Lalani; John Sarantopoulos
PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients
Edwin Sandanaraj; Suman Lal; Viknesvaran Selvarajan; London Lucien Ooi; Zee Wan Wong; Nan Soon Wong; Peter Cher Siang Ang; Edmund J.D. Lee; Balram Chowbay
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu; Robert J. Morgan; Lucille Leong; Dean Lim; Mark McNamara; Jana Portnow; Paul Frankel; David D. Smith; James H. Doroshow; David R. Gandara; Ana Aparicio; George Somlo; Carol Wong
Cancer Prevention and Susceptibility
Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families
Femke A. de Snoo; D. Timothy Bishop; Wilma Bergman; Inge van Leeuwen; Clasine van der Drift; Frans A. van Nieuwpoort; Coby J. Out-Luiting; Hans F. Vasen; Jeanet A.C. ter Huurne; Rune R. Frants; Rein Willemze; Martijn H. Breuning; Nelleke A. Gruis
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds